MAZE THERAPEUTICS, INC. Financing Cash Flow
MAZE THERAPEUTICS, INC. (MAZE) reported Financing Cash Flow of $189.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- MAZE THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $147.44M, a 23990.85% increase year-over-year.
- MAZE THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $42.36M, a 66.75% decline year-over-year.
- MAZE THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $3.59M, a 94.89% decline year-over-year.
- MAZE THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $143.76M.
- MAZE THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $275.34M, a 196.55% increase from fiscal 2024.
- MAZE THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $92.85M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $147.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $189.79M 10-Q · filed 2026-08-11 | $193.38M derived: sum of 3 quarters · filed 2026-08-11 | $337.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $42.36M 10-Q · filed 2026-05-12 | $45.95M derived: sum of 2 quarters · filed 2026-05-12 | $189.70M derived: sum of 3 quarters · filed 2026-05-12 | $190.32M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $147.35M derived: sum of 2 quarters · filed 2026-03-25 | $147.96M derived: sum of 3 quarters · filed 2026-08-11 | $275.34M 10-K · filed 2026-03-25 |
| 2025-09-30 | $143.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $144.37M derived: sum of 2 quarters · filed 2026-08-11 | $271.75M 10-Q · filed 2025-11-06 | $342.01M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $612.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $127.99M 10-Q · filed 2026-08-11 | $198.25M derived: sum of 3 quarters · filed 2026-08-11 | $196.10M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $127.38M 10-Q · filed 2026-05-12 | $197.64M derived: sum of 2 quarters · filed 2026-05-12 | $195.49M derived: sum of 3 quarters · filed 2026-05-12 | $195.64M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $70.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $68.11M derived: sum of 2 quarters · filed 2026-03-25 | $68.27M derived: sum of 3 quarters · filed 2026-03-25 | $92.85M 10-K · filed 2026-03-25 |
| 2024-09-30 | -$2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.00M derived: sum of 2 quarters · filed 2025-11-06 | $22.59M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $154.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $24.73M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $24.58M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |